Cargando…

Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation

BACKGROUND: Shenmai injection (SMI) has been used in the treatment of cardiovascular disease (CVD), such as heart failure, myocardial ischemia and coronary heart disease. It has been found to have efficacy on doxorubicin (DOX)-induced cardiomyopathy. The aims of this study were to explore the underl...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lin, Yang, Dongli, Li, Jinghao, Niu, Lu, Chen, Ye, Zhao, Xin, Oduro, Patrick Kwabena, Wei, Chun, Xu, Zongpei, Wang, Qilong, Li, Yuhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158159/
https://www.ncbi.nlm.nih.gov/pubmed/32293408
http://dx.doi.org/10.1186/s12906-020-02905-8
_version_ 1783522482924290048
author Li, Lin
Yang, Dongli
Li, Jinghao
Niu, Lu
Chen, Ye
Zhao, Xin
Oduro, Patrick Kwabena
Wei, Chun
Xu, Zongpei
Wang, Qilong
Li, Yuhong
author_facet Li, Lin
Yang, Dongli
Li, Jinghao
Niu, Lu
Chen, Ye
Zhao, Xin
Oduro, Patrick Kwabena
Wei, Chun
Xu, Zongpei
Wang, Qilong
Li, Yuhong
author_sort Li, Lin
collection PubMed
description BACKGROUND: Shenmai injection (SMI) has been used in the treatment of cardiovascular disease (CVD), such as heart failure, myocardial ischemia and coronary heart disease. It has been found to have efficacy on doxorubicin (DOX)-induced cardiomyopathy. The aims of this study were to explore the underlying molecular mechanisms of SMI treatment on CVD by using network pharmacology and its protective effect on DOX-induced cardiotoxicity by in vitro and in vivo experiment based on network pharmacology prediction. METHODS: Network pharmacology method was used to reveal the relationship between ingredient-target-disease and function-pathway of SMI on the treatment of CVD. Chemical ingredients of SMI were collected form TCMSP, BATMAN-TCM and HIT Database. Drugbank, DisGeNET and OMIM Database were used to obtain potential targets for CVD. Networks were visualized utilizing Cytoscape software, and the enrichment analysis was performed using IPA system. Finally, cardioprotective effects and predictive mechanism confirmation of SMI were investigated in H9c2 rat cardiomyocytes and DOX-injured C57BL/6 mice. RESULTS: An ingredient-target-disease & function-pathway network demonstrated that 28 ingredients derived from SMI modulated 132 common targets shared by SMI and CVD. The analysis of diseases & functions, top pathways and upstream regulators indicated that the cardioprotective effects of SMI might be associated with 28 potential ingredients, which regulated the 132 targets in cardiovascular disease through regulation of G protein-coupled receptor signaling. In DOX-injured H9c2 cardiomyocytes, SMI increased cardiomyocytes viability, prevented cell apoptosis and increased PI3K and p-Akt expression. This protective effect was markedly weakened by PI3K inhibitor LY294002. In DOX-treated mice, SMI treatment improved cardiac function, including enhancement of ejection fraction and fractional shortening. CONCLUSIONS: Collectively, the protective effects of SMI on DOX-induced cardiotoxicity are possibly related to the activation of the PI3K/Akt pathway, as the downstream of G protein-coupled receptor signaling pathway.
format Online
Article
Text
id pubmed-7158159
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71581592020-04-21 Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation Li, Lin Yang, Dongli Li, Jinghao Niu, Lu Chen, Ye Zhao, Xin Oduro, Patrick Kwabena Wei, Chun Xu, Zongpei Wang, Qilong Li, Yuhong BMC Complement Med Ther Research Article BACKGROUND: Shenmai injection (SMI) has been used in the treatment of cardiovascular disease (CVD), such as heart failure, myocardial ischemia and coronary heart disease. It has been found to have efficacy on doxorubicin (DOX)-induced cardiomyopathy. The aims of this study were to explore the underlying molecular mechanisms of SMI treatment on CVD by using network pharmacology and its protective effect on DOX-induced cardiotoxicity by in vitro and in vivo experiment based on network pharmacology prediction. METHODS: Network pharmacology method was used to reveal the relationship between ingredient-target-disease and function-pathway of SMI on the treatment of CVD. Chemical ingredients of SMI were collected form TCMSP, BATMAN-TCM and HIT Database. Drugbank, DisGeNET and OMIM Database were used to obtain potential targets for CVD. Networks were visualized utilizing Cytoscape software, and the enrichment analysis was performed using IPA system. Finally, cardioprotective effects and predictive mechanism confirmation of SMI were investigated in H9c2 rat cardiomyocytes and DOX-injured C57BL/6 mice. RESULTS: An ingredient-target-disease & function-pathway network demonstrated that 28 ingredients derived from SMI modulated 132 common targets shared by SMI and CVD. The analysis of diseases & functions, top pathways and upstream regulators indicated that the cardioprotective effects of SMI might be associated with 28 potential ingredients, which regulated the 132 targets in cardiovascular disease through regulation of G protein-coupled receptor signaling. In DOX-injured H9c2 cardiomyocytes, SMI increased cardiomyocytes viability, prevented cell apoptosis and increased PI3K and p-Akt expression. This protective effect was markedly weakened by PI3K inhibitor LY294002. In DOX-treated mice, SMI treatment improved cardiac function, including enhancement of ejection fraction and fractional shortening. CONCLUSIONS: Collectively, the protective effects of SMI on DOX-induced cardiotoxicity are possibly related to the activation of the PI3K/Akt pathway, as the downstream of G protein-coupled receptor signaling pathway. BioMed Central 2020-04-15 /pmc/articles/PMC7158159/ /pubmed/32293408 http://dx.doi.org/10.1186/s12906-020-02905-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Li, Lin
Yang, Dongli
Li, Jinghao
Niu, Lu
Chen, Ye
Zhao, Xin
Oduro, Patrick Kwabena
Wei, Chun
Xu, Zongpei
Wang, Qilong
Li, Yuhong
Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation
title Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation
title_full Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation
title_fullStr Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation
title_full_unstemmed Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation
title_short Investigation of cardiovascular protective effect of Shenmai injection by network pharmacology and pharmacological evaluation
title_sort investigation of cardiovascular protective effect of shenmai injection by network pharmacology and pharmacological evaluation
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158159/
https://www.ncbi.nlm.nih.gov/pubmed/32293408
http://dx.doi.org/10.1186/s12906-020-02905-8
work_keys_str_mv AT lilin investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT yangdongli investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT lijinghao investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT niulu investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT chenye investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT zhaoxin investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT oduropatrickkwabena investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT weichun investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT xuzongpei investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT wangqilong investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation
AT liyuhong investigationofcardiovascularprotectiveeffectofshenmaiinjectionbynetworkpharmacologyandpharmacologicalevaluation